Arca
Skip to content

Autism spectrum disorder

Drug research and approvals for autism spectrum disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 349 studies of autism spectrum disorder are recruiting on ClinicalTrials.gov, Health Canada has authorized 18 drug trials for it since 2013, and the EU has 1 authorised medicine for it.

  • Recruiting worldwide: 349
  • Trials authorized in Canada: 18
  • FDA orphan approvals: 0
  • EU medicines: 1

Recruiting Now

Newest start dates first, of 349 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 18; search them all in Canada trials
Aug 19, 2026A phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, tolerability, and pharmacokinetics of karxt +…XANOMELINE-TROSPIUM (KARXT, BMS-986510) / XANOMELINE (KARXT-EC, BMS-986519)Bristol-Myers SquibbPending
Apr 2, 2026A randomized, placebo-controlled trial of ppf3 vs. placebo in the treatment of children and adolescents with neurodevelopmental disordersPPF3HOLLAND BLOORVIEW KIDS REHABILITATION HOSPITALPending
Mar 27, 2024Psilocybin for treatment-resistant depression in autism: a pilot trial with pre-post brain and cognitive measurement to understand mechanisms (pat-da)PSILOCYBIN (PEX010)CENTRE FOR ADDICTION AND MENTAL HEALTHOngoing
Oct 19, 2023An open-label extension study to investigate safety and tolerability of ml-004 in adolescents and adults with autism spectrum disorder (asd)ZOLMITRIPTAN (ML-004)MAPLIGHT THERAPEUTICS, INC.Ongoing
Dec 23, 2021A randomized, double-blind, parallel group, placebo-controlled study to investigate the efficacy, safety, and tolerability of ml-004 in adolescents and adults…ZOLMITRIPTAN (ML-004)MAPLIGHT THERAPEUTICS, INC.Closed
Aug 17, 2021Imaging alterations in synaptic density in autism spectrum disorder using a novel synaptic vesicular protein 2a tracer [18f]synvest-1[F-18]SDM-8CENTRE FOR ADDICTION AND MENTAL HEALTHOngoing
May 26, 2021An exploratory, phase 2, randomized, double-blind, placebo-controlled trial to investigate the safety and efficacy of cannabidiol oral solution (gwp42003p;…CANNABIS (CANNABIDIOL;GWP42003-P)GW RESEARCH LIMITEDClosed
Mar 16, 2021A randomized placebo-controlled trial of sertraline vs. placebo in the treatment of anxiety in children and adolescents with neurodevelopmental disordersSERTRALINEDR EVDOKIA ANAGNOSTOUOngoing
Jul 10, 2020A phase II multicenter, randomized, double-blind, 12-week treatment, 3-arm, parallel-group, placebo-controlled study to investigate the efficacy, safety and…ALOGABAT (RO7017773)RocheClosed
May 7, 2019Deep brain stimulation for the treatment of refractory repetitive self-injurious behaviour in children with autism spectrum disorder. a pilot project.GLUCOVISION ([F18]-FDG PHOSPHATE, [F18]-FDG CITRATE)THE HOSPITAL FOR SICK CHILDRENOngoing

Medicines Authorised in the EU

Newest first
AuthorisedMedicineHolderEPAR
Sep 20, 2018SlenytomelatoninRAD Neurim Pharmaceuticals EEC SARLEMA ↗

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.